Status:
COMPLETED
WOE of Anti-CD20 Therapies
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
21-85 years
Brief Summary
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, n...
Detailed Description
This will be a non-interventional, primary data collection study in patients with MS treated with an established anti-CD20 treatment regimen (OCR or OMB) in the United States. Patients who satisfy the...
Eligibility Criteria
Inclusion
- OCR sample:
- Self-reported diagnosis of RMS, SPMS or CIS
- ≥21 years old at the time of initial contact
- Under treatment with OCR at the time of initial contact
- Have been on OCR for ≥ 1 year at the time of initial contact (i.e., prevalent users)
- Able to answer the questionnaires in English
- OMB sample
- Self-reported diagnosis of RMS, SPMS or CIS
- ≥21 years old at the time of initial contact
- Under treatment with OMB at the time of initial contact
- Have been on OMB for ≥6 months at the time of initial contact (i.e., prevalent users)
- Able to answer the questionnaires in English
Exclusion
- OCR sample:
- Currently participating in a clinical trial involving MS drugs
- Last Ocrevus infusion was less than 3 months back
- OMB sample:
- Currently participating in a clinical trial involving MS drugs
Key Trial Info
Start Date :
December 4 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 13 2025
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT06121349
Start Date
December 4 2023
End Date
June 13 2025
Last Update
July 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936